Aquestive Therapeutics, Inc. (AQST) financial statements (2021 and earlier)

Company profile

Business Address 30 TECHNOLOGY DRIVE
WARREN, NJ 07059
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments324961
Cash and cash equivalents324961
Receivables340
Inventory, net of allowances, customer advances and progress billings235
Inventory235
Deferred costs 05
Other undisclosed current assets7123
Total current assets:456874
Noncurrent Assets
Operating lease, right-of-use asset3 
Property, plant and equipment71012
Intangible assets, net (including goodwill)000
Intangible assets, net (excluding goodwill)000
Other noncurrent assets800
Total noncurrent assets:181013
TOTAL ASSETS:637887
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities161828
Accounts payable71220
Accrued liabilities957
Deferred revenue11
Debt3 5
Other undisclosed current liabilities2 1
Total current liabilities:211933
Noncurrent Liabilities
Long-term debt and lease obligation376043
Long-term debt, excluding current maturities346043
Operating lease, liability3 
Liabilities, other than long-term debt661
Deferred revenue44
Asset retirement obligations 11
Other liabilities2  
Other undisclosed noncurrent liabilities48  
Total noncurrent liabilities:906644
Total liabilities:1118577
Stockholders' equity
Stockholders' equity attributable to parent(48)(6)10
Common stock000
Additional paid in capital13812471
Accumulated deficit(186)(130)(61)
Total stockholders' equity:(48)(6)10
TOTAL LIABILITIES AND EQUITY:637887

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
Revenues465367
Cost of revenue
(Cost of Goods and Services Sold)
(13)  
Gross profit:335367
Operating expenses(76)(105)(116)
Operating loss:(43)(53)(49)
Nonoperating income (expense)0 (0)
Investment income, nonoperating0  
Other nonoperating expense  (0)
Interest and debt expense(11)(14)(8)
Loss from continuing operations before equity method investments, income taxes:(54)(67)(57)
Other undisclosed income (loss) from continuing operations before income taxes(2)1(5)
Net loss available to common stockholders, diluted:(56)(66)(61)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
Net loss:(56)(66)(61)
Comprehensive loss, net of tax, attributable to parent:(56)(66)(61)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: